In several types of cancer, PD-L1 expression is used as a predictive biomarker for immune checkpoint inhibitors; however, in CRC, deficient mismatch repair/microsatellite instability (dMMR/MSI) status is considered a superior predictor of treatment response than levels of PD-L1 expression. Here, CD274 is linked to cancer.